(ECL) Ecolab - Ratings and Ratios
Water,Disinfectants,Sanitizers,Pest Control
ECL EPS (Earnings per Share)
ECL Revenue
Description: ECL Ecolab
Ecolab Inc. is a leading provider of water, hygiene, and infection prevention solutions and services globally, operating through four key segments: Global Industrial, Global Institutional & Specialty, Global Healthcare & Life Sciences, and Global Pest Elimination. The companys diverse product portfolio and services cater to various industries, including manufacturing, food and beverage processing, healthcare, and hospitality.
From a business perspective, Ecolabs strengths lie in its comprehensive offerings, which address the growing need for cleanliness, hygiene, and infection prevention across different sectors. The companys brand portfolio, including Ecolab, Bioquell, Purolite, and Anios, provides a robust foundation for its market presence. Key Performance Indicators (KPIs) that could be used to evaluate Ecolabs performance include revenue growth, segment-wise profitability, customer retention rates, and the ratio of recurring revenue to total revenue.
To further analyze Ecolabs financial health and operational efficiency, metrics such as operating margin, return on equity (RoE) of 24.40%, and debt-to-equity ratio can be examined. The companys ability to generate cash flows, as indicated by its market capitalization of $76.24 billion, is another crucial aspect. Ecolabs price-to-earnings (P/E) ratio of 36.64 and forward P/E of 35.59 suggest that investors have certain expectations regarding the companys future earnings growth.
From a strategic standpoint, Ecolabs focus on innovation, customer service, and sustainability could be critical in driving its long-term success. The companys commitment to delivering end-to-end solutions that address the complex needs of its customers across different industries positions it well for growth. As the demand for hygiene and infection prevention continues to evolve, Ecolabs adaptability and investment in research and development will be key factors in maintaining its competitive edge.
ECL Stock Overview
| Market Cap in USD | 80,473m |
| Sub-Industry | Specialty Chemicals |
| IPO / Inception | 1988-01-05 |
ECL Stock Ratings
| Growth Rating | 47.7% |
| Fundamental | 74.5% |
| Dividend Rating | 57.0% |
| Return 12m vs S&P 500 | -4.35% |
| Analyst Rating | 3.73 of 5 |
ECL Dividends
| Dividend Yield 12m | 1.20% |
| Yield on Cost 5y | 1.70% |
| Annual Growth 5y | 4.54% |
| Payout Consistency | 96.7% |
| Payout Ratio | 37.0% |
ECL Growth Ratios
| Growth Correlation 3m | 65.2% |
| Growth Correlation 12m | 61.9% |
| Growth Correlation 5y | 48.1% |
| CAGR 5y | 8.24% |
| CAGR/Max DD 5y | 0.19 |
| Sharpe Ratio 12m | 1.37 |
| Alpha | 0.06 |
| Beta | 0.613 |
| Volatility | 19.43% |
| Current Volume | 925.3k |
| Average Volume 20d | 1060.2k |
| Stop Loss | 268.7 (-3%) |
| Signal | -1.86 |
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income (2.14b TTM) > 0 and > 6% of Revenue (6% = 943.4m TTM) |
| FCFTA 0.07 (>2.0%) and ΔFCFTA -3.03pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 13.78% (prev 12.18%; Δ 1.60pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.11 (>3.0%) and CFO 2.62b > Net Income 2.14b (YES >=105%, WARN >=100%) |
| Net Debt (7.05b) to EBITDA (3.95b) ratio: 1.78 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.44 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (285.4m) change vs 12m ago -0.56% (target <= -2.0% for YES) |
| Gross Margin 43.97% (prev 42.60%; Δ 1.37pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 69.58% (prev 72.85%; Δ -3.27pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 9.60 (EBITDA TTM 3.95b / Interest Expense TTM 312.9m) >= 6 (WARN >= 3) |
Altman Z'' 3.91
| (A) 0.09 = (Total Current Assets 7.08b - Total Current Liabilities 4.91b) / Total Assets 23.74b |
| (B) 0.51 = Retained Earnings (Balance) 12.08b / Total Assets 23.74b |
| (C) 0.13 = EBIT TTM 3.00b / Avg Total Assets 22.60b |
| (D) 0.73 = Book Value of Equity 10.44b / Total Liabilities 14.39b |
| Total Rating: 3.91 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 74.48
| 1. Piotroski 6.0pt = 1.0 |
| 2. FCF Yield 1.81% = 0.91 |
| 3. FCF Margin 10.01% = 2.50 |
| 4. Debt/Equity 0.90 = 2.11 |
| 5. Debt/Ebitda 2.12 = -0.23 |
| 6. ROIC - WACC 7.42% = 9.28 |
| 7. RoE 23.99% = 2.00 |
| 8. Rev. Trend 60.32% = 3.02 |
| 9. Rev. CAGR 3.42% = 0.43 |
| 10. EPS Trend 73.71% = 1.84 |
| 11. EPS CAGR 16.31% = 1.63 |
What is the price of ECL shares?
Over the past week, the price has changed by -2.36%, over one month by +6.80%, over three months by +5.08% and over the past year by +11.88%.
Is Ecolab a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ECL is around 265.18 USD . This means that ECL is currently overvalued and has a potential downside of -4.28%.
Is ECL a buy, sell or hold?
- Strong Buy: 8
- Buy: 4
- Hold: 13
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the ECL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 283.9 | 2.5% |
| Analysts Target Price | 283.9 | 2.5% |
| ValueRay Target Price | 293.2 | 5.8% |
Last update: 2025-08-26 04:35
ECL Fundamental Data Overview
CCE Cash And Equivalents = 1.92b USD (last quarter)
P/E Trailing = 37.8812
P/E Forward = 37.7358
P/S = 5.1179
P/B = 8.6342
P/EG = 3.43
Beta = 1.069
Revenue TTM = 15.72b USD
EBIT TTM = 3.00b USD
EBITDA TTM = 3.95b USD
Long Term Debt = 7.52b USD (from longTermDebt, last quarter)
Short Term Debt = 844.6m USD (from shortTermDebt, last quarter)
Debt = 8.37b USD (Calculated: Short Term 844.6m + Long Term 7.52b)
Net Debt = 7.05b USD (from netDebt column, last quarter)
Enterprise Value = 86.92b USD (80.47b + Debt 8.37b - CCE 1.92b)
Interest Coverage Ratio = 9.60 (Ebit TTM 3.00b / Interest Expense TTM 312.9m)
FCF Yield = 1.81% (FCF TTM 1.57b / Enterprise Value 86.92b)
FCF Margin = 10.01% (FCF TTM 1.57b / Revenue TTM 15.72b)
Net Margin = 13.59% (Net Income TTM 2.14b / Revenue TTM 15.72b)
Gross Margin = 43.97% ((Revenue TTM 15.72b - Cost of Revenue TTM 8.81b) / Revenue TTM)
Tobins Q-Ratio = 8.33 (Enterprise Value 86.92b / Book Value Of Equity 10.44b)
Interest Expense / Debt = 0.91% (Interest Expense 76.2m / Debt 8.37b)
Taxrate = 17.09% (from yearly Income Tax Expense: 439.3m / 2.57b)
NOPAT = 2.49b (EBIT 3.00b * (1 - 17.09%))
Current Ratio = 1.44 (Total Current Assets 7.08b / Total Current Liabilities 4.91b)
Debt / Equity = 0.90 (Debt 8.37b / last Quarter total Stockholder Equity 9.32b)
Debt / EBITDA = 2.12 (Net Debt 7.05b / EBITDA 3.95b)
Debt / FCF = 5.32 (Debt 8.37b / FCF TTM 1.57b)
Total Stockholder Equity = 8.90b (last 4 quarters mean)
RoA = 9.00% (Net Income 2.14b, Total Assets 23.74b )
RoE = 23.99% (Net Income TTM 2.14b / Total Stockholder Equity 8.90b)
RoCE = 18.29% (Ebit 3.00b / (Equity 8.90b + L.T.Debt 7.52b))
RoIC = 14.98% (NOPAT 2.49b / Invested Capital 16.63b)
WACC = 7.56% (E(80.47b)/V(88.84b) * Re(8.27%)) + (D(8.37b)/V(88.84b) * Rd(0.91%) * (1-Tc(0.17)))
Shares Correlation 5-Years: -90.0 | Cagr: -0.36%
Discount Rate = 8.27% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 79.13% ; FCFE base≈1.77b ; Y1≈1.99b ; Y5≈2.67b
Fair Price DCF = 156.3 (DCF Value 44.32b / Shares Outstanding 283.6m; 5y FCF grow 14.34% → 3.0% )
Revenue Correlation: 60.32 | Revenue CAGR: 3.42%
Rev Growth-of-Growth: -4.81
EPS Correlation: 73.71 | EPS CAGR: 16.31%
EPS Growth-of-Growth: -17.49
Additional Sources for ECL Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle